相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial
Jifang Gong et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
Caicun Zhou et al.
LANCET ONCOLOGY (2022)
CS1001-304: A phase III study of fluorouracil and cisplatin (FP) with CS1001, an anti-PD-L1 antibody, or placebo in unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
Li Jin et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Next generation of immune checkpoint inhibitors and beyond
Julian A. Marin-Acevedo et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
The preclinical characterization of CS1001, an anti-PD-L1 IgG4 monoclonal antibody and its activity beyond T cell regulation
Juan Zhang et al.
CANCER RESEARCH (2020)
Preliminary Results from a Multicenter, Single-Arm, Phase 2 Study of CS1001, an Anti-Programmed Death-Ligand 1 (PD-L1) Human Monoclonal Antibody (mAb), in Patients (pts) with Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma (rr-ENKTL)
Hui-qiang Huang et al.
BLOOD (2019)